Skip to main content
Download PDF

Serotoninergic receptor ligands improve Tamoxifen effectiveness on breast cancer cells

BMC Cancer volume 22, Article number: 171 (2022) Cite this article

Abstract

Background

Serotonin (or 5-Hydroxytryptamine, 5-HT) signals in mammary gland becomes dysregulated in cancer, also contributing to proliferation, metastasis, and angiogenesis. Thus, the discovery of novel compounds targeting serotonin signaling may contribute to tailor new therapeutic strategies usable in combination with endocrine therapies. We have previously synthesized serotoninergic receptor ligands (SER) with high affinity and selectivity towards 5-HT2A and 5-HT2C receptors, the main mediators of mitogenic effect of serotonin in breast cancer (BC). Here, we investigated the effect of 10 SER on viability of MCF7, SKBR3 and MDA-MB231 BC cells and focused on their potential ability to affect Tamoxifen responsiveness in ER+ cells.

Methods

Cell viability has been assessed by sulforhodamine B assay. Cell cycle has been analyzed by flow cytometry. Gene expression of 5-HT receptors and Connective Tissue Growth Factor (CTGF) has been checked by RT-PCR; mRNA levels of CTGF and ABC transporters have been further measured by qPCR. Protein levels of 5-HT2C receptors have been analyzed by Western blot. All data were statistically analyzed using GraphPad Prism 7.

Results

We found that treatment with SER for 72 h reduced viability of BC cells. SER were more effective on MCF7 ER+ cells (IC50 range 10.2 μM - 99.2 μM) compared to SKBR3 (IC50 range 43.3 μM - 260 μM) and MDA-MB231 BC cells (IC50 range 91.3 μM - 306 μM). This was paralleled by accumulation of cells in G0/G1 phase of cell cycle. Next, we provided evidence that two ligands, SER79 and SER68, improved the effectiveness of Tamoxifen treatment in MCF7 cells and modulated the expression of CTGF, without affecting viability of MCF10A non-cancer breast epithelial cells. In a cell model of Tamoxifen resistance, SER68 also restored drug effect independently of CTGF.

Conclusions

These results identified serotoninergic receptor ligands potentially usable in combination with Tamoxifen to improve its effectiveness on ER+ BC patients.

Peer Review reports

Background

Serotonin (5-HT) is a biogenic amine acting as neurotransmitter in the nervous system both at central and peripheral level [1,2,3,4]. Besides playing a role in several physiological and pathological processes, including circadian rhythms, sexual and feeding behavior, thermoregulation and cardiovascular function [5,6,7,8,9], 5-HT acts as trophic, mitogenic and anti-apoptotic factor for a wide range of normal and tumor cells [10,11,12,13]. Indeed, a growth stimulatory effect of 5-HT on prostate, small-cell lung, colorectal, hepatocellular and breast carcinoma, cholangiocarcinoma, glioma, bladder cancer and ovarian tumors has been described [14]. 5-HT also promotes cancer cell migration, invasiveness and angiogenesis [15]. The multiple, sometimes opposing, actions of serotonin occur through the interaction with a wide range of receptors. Indeed, with the exception of 5-HT3, the unique receptor involving an ion channel that regulates the flow of sodium and potassium ions, six classes of 5-HT receptors - including additional subclasses - named 5-HT1, 5-HT2, 5-HT4, 5-HT5, 5-HT6 and 5-HT7, are G-protein-coupled [16]. More often the mitogenic effect of 5-HT is mediated by 5-HT1 and 5-HT2 receptors while less frequently through 5-HT4 and 5-HT6 [15]. Serotonin plays a central role in mammary gland ensuring epithelial homeostasis during changes associated with pregnancy, lactation and involution [17]. Thus, an extensive alteration of 5-HT signaling may contribute to breast cancer (BC) phenotype [15]. Of note, BC cells produce and secrete high levels of serotonin that, interfering with mitochondria biogenesis, confers proliferative advantages [18]. BC is the most common cancer in women worldwide [19], with estrogen receptor positive (ER+) BC representing approximately 75% of all diagnosed cancers [20]. About the latter, the predominant treatment strategy consists in the inhibition of ER pathway at various levels, including the use of selective estrogen receptor modulators (SERMs), like Tamoxifen, to directly antagonize the receptor [21]. However, Tamoxifen effectiveness may be modulated by the interaction with several drugs, including those acting on serotonin signaling. Nevertheless, serotonin action has also been targeted by using 5-HT antagonists and/or uptake inhibitors to prevent cancer cell growth [15]. Our research group has been involved in the synthesis of serotoninergic receptor ligands (SER) with high affinity and selectivity [22,23,24,25]. Here, we analyzed a set of previously synthetized SER with affinity and selectivity binding profile towards 5-HT2A and 5-HT2C receptors, known as mediators of mitogenic effect of serotonin in BC cells [18, 26]. We found that some of these serotoninergic receptor ligands improve Tamoxifen responsiveness in MCF7 BC cells and that such effect occurs through the modulation of CTGF (Connective Tissue Growth Factor) expression. Overall, these results suggest these compounds as new serotoninergic receptor ligands potentially useful to ameliorate Tamoxifen effectiveness in ER+ BC cells.

Methods

Materials

Media, sera and antibiotics for cell culture were from Lonza (Basel, Switzerland). Reagents and substituted piperazines for synthesis of SER, Estradiol and Tamoxifen for cell treatments and all other chemicals were from Sigma-Aldrich (St Louis, MO, USA). TRIzol solution for RNA isolation, SuperScript III Reverse Transcriptase with oligo dT primers for RNA reverse transcription and AmpliTaq Gold for RT-PCR were from Life Technologies (Carlsbad, CA, USA). iTaq Universal SYBR Green Supermix for Quantitative Real-Time PCR (qPCR) was from Biorad (Hercules, CA, USA). 5HT2C and Vinculin antibodies for Western Blot were from Santa Cruz (Dallas, TX, USA). Secondary antibody (Anti-mouse 1:2000) was purchased from Bio-Rad (Hercules, CA, USA).

Synthesis of serotoninergic receptor ligands and in vitro receptor binding

All reactions were monitored by TLC, carried out on Merck 60G F254 plates with fluorescent indicator and the plates were visualized with UV light (254 nm). Each final compound and intermediate was purified by silica gel column chromatography (Macherey-Nagel 60 0,063–0,2 mm/70–230 mesh). Some final compounds were obtained in a pure form after conversion in the corresponding hydrochloride salts. 1H-NMR and 13C-NMR spectra were recorded on Varian Mercury Plus 400 MHz instrument. Unless otherwise stated, all spectra were recorded in CDCl3. Chemical shifts are reported in ppm using Me4Si as internal standard. The following abbreviations are used to describe peak patterns when appropriate: s (singlet), d (doublet), t (triplet), m (multiplet), q (quartet), qt (quintet), dd (double doublet), ddd (double dd), bs (broad singlet). Mass spectra of the final products were performed on LTQ Orbitrap XL™ Fourier transform mass spectrometer (FTMS) equipped with ESI ION MAX™ source (Thermo Fisher, San José, USA). Melting points were determined using a Buchi B-540 hot-stage instrument and are uncorrected. Where analyses are indicated only by the symbols of the elements, results obtained are within ±0.4% of the theoretical values. Solutions were dried over Na2SO4 and concentrated with Buchi R-114 rotavapor at low pressure. Once synthesized, SER were tested for in vitro affinity for serotonin 5-HT1A, 5-HT2A and 5-HT2C receptors by radioligand binding assays. The more active compounds on serotonin receptors have been selected and evaluated for their affinity for dopaminergic (D1 and D2) and adrenergic (α1 and α2) receptors. All the compounds were dissolved in 5% DMSO. The following specific radioligands and tissue sources were used: (a)serotonin 5-HT1A receptor, [3H]-8-OH-DPAT, rat brain cortex; (b) serotonin 5-HT2A receptor, [3H]ketanserin, rat brain cortex; (c)serotonin 5-HT2C receptor, [3H]mesulergine, rat brain cortex. Non-specific binding was determined as described in the experimental section, and specific binding as the difference between total and non-specific binding. Blank experiments were carried out to determine the effect of 5% DMSO on the binding and no effects were observed. Competition experiments were analyzed by PRISM 5 (GraphPadPrism®, 1992–2007, GraphPad Software, Inc., La Jolla, CA, USA) to obtain the concentration of unlabeled drug that caused 50% inhibition of ligand binding (IC50), with six concentrations of test compounds, each performed in triplicate. The IC50 values obtained were used to calculate apparent inhibition constants (Ki) by the method of Cheng and Prussoff [27], from the following equation: Ki = IC50/(1 + S/KD) where S represents the concentration of the hot ligand used and KD its receptor dissociation constant (KD values, obtained by Scatchard analysis [28], were calculated for each labeled ligand). Radioligand binding assays for 5-HT1A were performed following a published procedure [29]. 5-HT2A and 5-HT2C binding assays were performed reported by Herndon et al. [30].

Cell cultures

MCF7 (ER+, PR+, HER2−), SKBR3 (ER−, PR+, HER2+) and MDA-MB231 (ER−, PR−, HER2−) human BC cells and MCF10A non-cancer breast epithelial cells were available in our laboratory. MCF7, SKBR3 and MDA-MB231 cells were cultured in DMEM, supplemented with 10% FBS, 2 mM glutamine, 100 units/ml penicillin and 100 units/ml streptomycin. MCF10A cells were cultured in MEBM, supplemented with 0.4% BPE, 0.1% hEGF, 0.1%, Insulin, 0.1% Hydrocortisone and 0.1% GA-1000. Cultures were maintained in a humidified atmosphere of 95% air and 5% CO2 at 37 °C. Treatment with SER were carried out in culture conditions. Treatment with Tamoxifen and/or SER were carried out upon 48 h estrogen starvation in phenol-red free medium supplemented with 10% Charcoal Stripped (C/S) FBS, 2 mM glutamine, 100 units/ml penicillin and 100 units/ml streptomycin.

Cell survival assay

Cells were fixed with 50% trichloroacetic acid for at least 2 h at 4 °C, washed with distilled and de-ionized water, air-dryed and stained 30 min with 0.4% sulforhodamine B in 1% acetic acid. Unbound dye was removed and 10 mM tris-HCl solution (pH 7.5) was added to dissolve the protein-bound dye. Cell survival was assessed by optical density determination at 510 nm using a microplate reader [31].

Establishing of Tamoxifen-resistant model (MCF7-R)

MCF7 cells were cultured for 4 months in phenol-red free medium supplemented with 10% (C/S) FBS and continuously exposed to Tamoxifen (1 μM). At the end, the acquisition of drug resistance was measured treating the cells with increasing concentration of Tamoxifen (100 nM to 6 μM) for 72 h before measuring cell survival by sulforhodamine B assay. To further validate the degree of drug resistance, the expression levels of ABCC1, ABCG1 and ABCG2 – members of ABC transporter family known as involved in multi-drug resistance – were evaluated by Quantitative Real-Time PCR (qPCR; see below) upon cell treatment with 5 μM Tamoxifen for 72 h.

Cytofluorimetric analysis

Cells were collected and fixed in 70% (v/v) ethanol for at least 2 h at −20 °C. Washed pellets were resuspended in phosphate-buffered saline (PBS) containing RNase A (1 μg/1 μL) and Propidium Iodide (1 μg/1 μL). The incubation was carried for 30 min at room temperature in a dark environment. Samples were analyzed for emission in the PE-Texas Red channel using BD LSR Fortessa (BD Biosciences, San Jose, CA, USA) and by BD FACS Diva software. 104 events for each sample were acquired in all analyses.

RNA isolation, RT-PCR and qPCR

Total RNA was isolated from cells, quantified (NanoDrop spectrophotometer, Life Technologies, Carlsbad, CA, USA) and reverse transcribed according to the manufacturer’s instructions. Specific primers pairs used for RT-PCR and qPCR assays were designed using Oligo 4.0. and listed in Table 1. Semiquantitative PCR and qPCR assays were performed according to manufacturer’s instructions for Bio-Rad T100 thermal cycler and CFX Connect Real Time system (Biorad, Hercules, CA, USA), respectively. Relative gene expression quantification was measured by 2−ΔΔCt method normalizing for the reference sample using Rps23 (Ribosomal Protein S23) as housekeeping gene.

Table 1 Primer pairs for qPCR
Full size table

Western Blot

RIPA buffer (Promega, Madison, Wisconsin, USA) was used for proteins’ extraction. Lysates (50–80 mg protein/sample) were blotted with anti-5HT2C (1:500). Total lysates were normalized using anti-Vinculin (1:10000). The autoradiographs shown were obtained by ECL kit (Bio-Rad, Hercules, CA, USA).

Statistical analysis

All the statistical analyses were carried out using GraphPad Prism 7. Kruskal Wallis test followed by Dunn’s correction was applied for multiple comparisons. Wilcoxon signed rank tests was assessed for comparison to a hypothetical value. Mann-Whitney test was used for pairwise comparisons. P-value<0.05 was considered statistically significant.

Results

Synthesis and in vitro receptor binding of serotoninergic receptor ligands

The synthetic strategy used for SER preparation (Fig. 1) was previously described [22,23,24,25]. Synthesized SER showed affinities in the nanomolar range towards 5-HT1A, 5-HT2A and 5-HT2C receptors (Table 2). Besides the outstanding 5-HT2A receptor affinity and selectivity of compound SER142 (0.046 nM), other interesting Ki values were those of compounds SER137 (1.07 nM), SER196 (1.68 nM), SER195 (45.3 nM), SER167 (48.5 nM), and SER198 (77.8 nM) a picolinic derivative linked to bis(4-fluorophenyl) methyl piperazine moiety through to a propyl chain spacer. Instead, the analogue derivative characterized by a shorter ethyl chain spacer (SER177) showed a favorable affinity profile for 5-HT2C receptors with Ki value of 0.8 nM. Other interesting Ki values towards this receptor, were those of compound SER68 characterized by 3,4-dichlorophenyl group as N-4 piperazine substituent, linked through an ethyl chain to a norbornene fragment that conferred affinity and selectivity toward 5-HT2C receptor with Ki value of 1.13 nM. Instead, the norbornene derivative 4-[3-[4-(2-furoyl)piperazin-1-yl]propoxy-2-ol]-4-aza-tricyclo [5.2.1.02,6]dec-8-ene-3,5-dione (SER31) characterized by 2-hydroxy-propyl spacing unit was one of the most selective compound for the 5-HT2C receptor with Ki = 5.04 nM. Moreover, the N′-cyanopicolinamidine derivative SER79, characterized once again by the bis(4-fluorophenyl) methyl piperazine moiety, showed affinity in the nanomolar range towards 5-HT2C receptor (Ki = 21.4 nM) and weak or no affinity towards 5-HT2A and 5-HT1A receptors respectively.

Fig. 1
figure 1

Chemical structures of serotoninergic receptor ligands (SER)

Full size image
Table 2 Affinities of SER for 5-HT1A, 5-HT2A and 5-HT2C receptors (Ki ± SD; nM)
Full size table

Antiproliferative effect of serotoninergic receptor ligands on BC cell lines

SER137, SER142, SER167, SER195, SER196, SER198, SER79, SER177, SER31, SER68, endowed with different binding affinity for 5-HT2A and 5-HT2C receptors, were examined for their ability to affect BC cell viability. MCF7 (ER+, PR+, HER2−) cells were treated with raising concentration (1 μM, 5 μM, 15 μM, 50 μM, 100 μM) of SER, in agreement with previous report [32]. We found that all compounds determined a dose-dependent growth inhibition upon both 48- and 72-h treatment. None effect of vehicle (DMSO) on cell viability was observed (Fig. S1a). All SER at 100 μM dose (except for SER196) significantly reduced MCF7 cell viability upon 72 h (60 to 80%, adjp<0.05). Of note, the effectiveness of SER79 and SER198 on reducing MCF7 cell viability was also observed at lower dose 50 μM (≈70%; adjp<0.05). Consistently, IC50 values were 24.11 μM and 10.25 μM for SER79 and SER198, respectively. For the other compounds IC50 ranged between 53.28 μM and 99.2 μM. Finally, IC50 value estimated for SER196 was 123.8 μM, out of concentration range tested (Fig. 2).

Fig. 2
figure 2

Effect of SER on MCF7 cell viability. MCF7 cells were treated with raising concentration (1 μM, 5 μM, 15 μM, 50 μM, 100 μM) of SER137, SER142, SER167, SER195, SER196, SER198, SER79, SER177, SER31, SER68. After 48 and 72 h, cell viability was assessed by sulforhodamine B assay (see Methods). The results were reported as percentage of viable cells compared to positive control (untreated cells), considered as maximum viability (100%). Data represent the mean ± SD of at least five independent triplicate experiments. * denotes statistically significant values compared with positive control (*adjp<0.05,**adjp<0.01,***adjp<0.001)

Full size image

We also evaluated the impact of SER137, SER142, SER167, SER195, SER196, SER198, SER79, SER177, SER31, SER68 on BC cell lines with different molecular features: SKBR3 (ER−, PR+, HER2+) and MDA-MB231 (ER−, PR−, HER2−). We observed that all SER at 100 μM dose significantly reduced SKBR3 cell viability. On the other hand, 50 μM SER79 and SER198 were able to significantly reduce SKBR3 cell viability (≈50%; adjp<0.05; Fig. 3). None effect of vehicle was observed (Fig. S1b). Such results highlighted that SER79 and SER198 were the most effective in reducing not only MCF7 but also SKBR3 cell viability. Of note, IC50 value estimated for SER79 and SER198 in SKBR3 cells was 53.56 μM and 67.74 μM, respectively. In parallel, we evaluated the effect of SER on triple negative MDA-MB231 cells. We found that only SER137, SER79, SER31, SER68 at 100 μM dose were able to inhibit triple negative MDA-MB231 cell growth. In the same condition, none effect of vehicle was observed (Fig. S1c). Notably, IC50 value estimated for SER79 in MDA-MB231 cells was 116.9 μM, higher than those obtained for both SKBR3 and MCF7 cells (Fig. 4). IC50 values estimated for SER in MCF7, SKBR3 and MDA-MB231 cells were listed in Table 3.

Fig. 3
figure 3

Effect of SER on SKBR3 cell viability. SKBR3 cells were treated with raising concentration (15 μM, 50 μM, 100 μM) of SER137, SER142, SER167, SER195, SER196, SER198, SER79, SER177, SER31, SER68. Cell viability was assessed, after 72 h, by sulforhodamine B assay (see Methods). The results were reported as percentage of viable cells compared to positive control (untreated cells), considered as maximum viability (100%). Data represent the mean ± SD of at least three independent triplicate experiments. * denotes statistically significant values compared with positive control (*adjp<0.05,**adjp<0.01)

Full size image
Fig. 4
figure 4

Effect of SER on MDA-MB231 cell viability. MDA cells were treated with raising concentration (15 μM, 50 μM, 100 μM) of SER137, SER142, SER167, SER195, SER196, SER198, SER79, SER177, SER31, SER68. Cell viability was assessed, after 72 h, by sulforhodamine B assay (see Methods). The results were reported as percentage of viable cells compared to positive control (untreated cells), considered as maximum viability (100%). Data represent the mean ± SD of at least three independent triplicate experiments. * denotes statistically significant values compared with positive control (*adjp<0.05)

Full size image
Table 3 IC50 values (μM) of SER in MCF7, SKBR3 and MDA-MB231 BC cell lines
Full size table

We also verified that the different effect of SER on BC cells was not attributable to a lack of expression of 5-HT receptors in SKBR3 and MDA-MB231 cells. Indeed, HT2A and HT2C receptors were detected in all cell lines suggesting that the different effect of SER on MCF7 (ER+, PR+, HER2−), SKBR3 (ER−, PR+, HER2+) and MDA-MB231 (ER−, PR−, HER2−) cells should be attributable to their different molecular features, which also give them a different degree of aggressiveness (Fig. 5).

Fig. 5
figure 5

Representative gel images of RT-PCR assays for the 5-HT2A and 5-HT2C genes in MCF7, SKBR3 and MDA-MB231 cell lines. Rps23 was used as reference gene. Images have been cropped to improve the clarity of presentation

Full size image

Effect of serotoninergic receptor ligands on MCF7 cell responsiveness to Tamoxifen

The effect of SER on cell viability was further investigated by analyzing cell cycle. At first, we observed that all SER, except for SER198, at dose corresponding to IC50 values, were able to induce cell cycle perturbation in MCF7 cells, causing a significant increase in the percentage of cells in G0/G1 phase, paralleled by a decrease of S phase (pval<0.05). Thus, all SER, except for SER198, affected cell viability and perturbed cell cycle (Figs. 2 and 6a). Therefore, we investigated their effect on MCF7 cell responsiveness to Tamoxifen by treating estrogen-starved cells with Tamoxifen and E2 in presence of SER. Notably, SER79 and SER68 further decreased cell viability compared with cells treated with Tamoxifen alone (≈15% with SER79 and ≈30% with SER68; pval<0.05; Fig. 6b). Then, we analyzed CTGF mRNA levels in MCF7 cells treated with SER. Interestingly, we found that in presence of SER79 and SER68, while not of the other compounds, CTGF mRNA levels were significantly lower compared with those in untreated cells (≈60% with SER79 and ≈80% with SER68; pval<0.05; Fig. 6c). Of note, we found that none of SER compounds (IC50 values) significantly affected SKBR3 and MDA-MB231 cell cycle. In addition, CTGF was also expressed in SKBR3 and MDA-MB231 cells and, at variance with MCF7 cells, no significant SER-induced change was observed (Fig. S2).

Fig. 6
figure 6

Effect of SER on MCF7 cell cycle and Tamoxifen response. a MCF7 cells were treated with SER137, SER142, SER167, SER195, SER196, SER198, SER79, SER177, SER31, SER68 at IC50 doses. After 72 h, cell cycle was assessed by Propidium Iodide staining (see Methods). The results were reported as percentage of cells in G0/G1, S and G2/M cell cycle phase. b Estrogen-starved MCF7 cells (48 h) were treated with Tamoxifen (5 μM) in presence of E2 (100nM) and selected SER (SER137, SER142, SER167, SER195, SER196, SER79, SER177, SER31, SER68) at IC50 dose. As positive control, the cells were treated with E2 and SER alone (without Tamoxifen, dotted line). After 72 h, cell viability was assessed by sulforhodamine B assay (see Methods). The results were reported as percentage of viable cells compared to positive control, considered as maximum viability (100%). c Estrogen-starved MCF7 cells (48 h) were treated with selected SER at IC50 doses in presence of E2 (100nM). After 72 h, mRNA levels of CTGF were determined by qPCR (see Methods and Table 1). Data were normalized on Ribosomal Protein S23 (Rps23) gene as internal standard and were reported as CTGF mRNA levels in MCF7 treated with SER relative to those in untreated cells (dotted line). a-c Data represent the mean ± SD of at least three independent triplicate experiments. * denotes statistically significant values compared with (a) percentage of untreated cells in G0/G1, S and G2/M cell cycle phase (*pval<0.05,**pval<0.01), (b) positive control (*adjp<0.05,**adjp <0.01,***adjp<0.001), (c) untreated cells (pval<0.05); # denotes statistically significant values compared with cells treated with Tamoxifen in absence of SER (#pval<0.05)

Full size image

To further study the effectiveness of SER79 and SER68 in ameliorating MCF7 responsiveness, we treated the cells with Tamoxifen in presence of SER doses lower than IC50 values (5 μM SER79; 20 μM or 5 μM SER68). We found that 5 μM SER79 and 20 μM SER68 further decreased cell viability compared with cells treated with Tamoxifen alone (≈15% with SER79 and ≈20% with SER68; pval<0.01; Fig. 7a). No further effect was elicited by 5 μM SER68. Interestingly, we observed that both 5 μM SER79 and 20 μM SER68 were able to significantly reduce CTGF expression (≈30% with SER79 and ≈50% with SER68; pval<0.05; Fig. 7b). We also tested the effect of these compounds on non-cancer breast epithelial cells MCF10A. No effect was detected on cell viability (Fig. 7c). Overall, these data suggested that SER79 and SER68 improve Tamoxifen responsiveness of MCF7 cells without affecting non-cancer cells (Fig. 7).

Fig. 7
figure 7

Effect of low doses of SER79 and SER68 on MCF7 and MCF10A cells. a Estrogen-starved MCF7 cells (48 h) were treated with Tamoxifen (5 μM) in presence of E2 (100nM) and SER79 (5 μM) or SER68 (20 μM, 5 μM). As positive control, the cells were treated with E2 and SER alone (without Tamoxifen, dotted line). After 72 h, cell viability was assessed by sulforhodamine B assay (see Methods). The results were reported as percentage of viable cells compared to positive control, considered as maximum viability (100%). b Estrogen-starved MCF7 cells (48 h) were treated with SER79 (5 μM) or SER68 (20 μM) in presence of E2 (100 nM). After 72 h, mRNA levels of CTGF were determined by qPCR (see Methods and Table 1). Data were normalized on Ribosomal Protein S23 (Rps23) gene as internal standard. Bars represent CTGF mRNA levels in MCF7 treated with SER relative to those in untreated cells (dotted line). c MCF10A non-cancer breast epithelial cells were treated with SER79 (5 μM) or SER68 (20 μM). After 72 h, cell viability was assessed by sulforhodamine B assay (see Methods). The results were reported as percentage of viable cells compared to untreated cells (dotted line), considered as maximum viability (100%). a-c Data represent the mean ± SD of at least three independent triplicate experiments. * denotes statistically significant values compared with (a) positive control (*adjp<0.05,**adjp<0.01), (b, c) untreated cells (*pval<0.05, *pval<0.01); # denotes statistically significant values compared with cells treated with Tamoxifen in absence of SER (#pval<0.01)

Full size image

Effect of SER on Tamoxifen responsiveness of drug-resistant MCF7 cells

To further investigate the effect of SER79 and SER68 on Tamoxifen responsiveness and CTGF expression in MCF7 cells, we obtained - by a continuous treatment of 10 days with 1 μM Tamoxifen – a cellular model less sensitive to the drug (Tamoxifen-cultured MCF7). We observed that 20 μM SER79, 20 μM and 40 μM SER68, while not 5 μM SER79, reduced viability of Tamoxifen-cultured MCF7 cells by about 40% (adjp<0.01; Fig. 8a). Tamoxifen treatment alone did not affect viability of these cells. However, in the presence of 20 μM SER79, 20 μM and 40 μM SER68, Tamoxifen elicited a further 40% reduction of viability, similar to that achieved in Tamoxifen-responsive MCF7 cells (adjp<0.01; Fig. 8b). No Tamoxifen effect was observed in the presence of 5 μM SER79 (Fig. 8b). In parallel, CTGF mRNA levels were significantly increased in Tamoxifen-cultured MCF7 cells (pval<0.001; Fig. 8c). Both SER68 and SER79 – at doses able to restore Tamoxifen responsiveness - significantly reduced CTGF to levels similar (for SER79) or significantly lower (for SER68) than those detected in Tamoxifen-responsive MCF7 cells (pval<0.05; Fig. 8c).

Fig. 8
figure 8

Effect of SER79 and SER68 on Tamoxifen-cultured MCF7 cells. MCF7 cells were cultured in presence of Tamoxifen (1 μM) for 10 days. Estrogen-starved MCF7 and Tamoxifen-cultured MCF7 cells (48 h) were (a-c) treated with SER79 (20 μM, 5 μM) or SER68 (40 μ, 20 μM), (b) treated with Tamoxifen (5 μM) in presence of SER79 (20 μM, 5 μM) or SER68 (40 μM, 20 μM). All treatments were carried out in presence of E2 (100 nM) for 72 h. As positive control, the cells were treated with (a-c) E2 alone or (b) E2 in absence or in presence of SER (as indicated, dotted line). a,b Cell viability was assessed by sulforhodamine B assay (see Methods). The results were reported as percentage of viable cells compared to positive control, considered as maximum viability (100%). c mRNA levels of CTGF were determined by qPCR (see Methods and Table 1). Data were normalized on Ribosomal Protein S23 (Rps23) gene as internal standard and reported as CTGF mRNA levels in Tamoxifen-cultured MCF7 relative to those in MCF7 cells (dotted line). a-c Graphs represent the mean ± SD of at least three independent triplicate experiments. * denotes statistically significant values compared with (a,b) positive control (*adjp<0.05, ** adjp<0.01) or (c) MCF7 cells (*pval<0.05); # denotes statistically significant values compared with (b) cells treated with Tamoxifen in absence of SER or (c) untreated Tamoxifen-cultured MCF7 cells (#pval<0.01, ##pval<0.0001)

Full size image

Next, we obtained Tamoxifen-resistant MCF7 cells (MCF7-R; see Materials and Methods). As reported in Supplementary Fig. 3, Tamoxifen did not reduce MCF7-R cell viability up to 6 mM. Moreover, Tamoxifen-treated MCF7-R cells displayed higher mRNA levels of ABCC1, ABCG1 and ABCG2, markers of multidrug resistance [32] (Fig. S3). If used alone, neither 20 μM SER79 neither 20 μM SER68 had effect onto MCF7-R cells (Fig. 9a). In co-treatment with 5 μM Tamoxifen, SER68 significantly reduced viability of MCF7-R cells (pval<0.01; Fig. 9b). No significant effect was achieved by co-treatment with Tamoxifen and SER79 (Fig. 9b). At variance with Tamoxifen-cultured cells, MCF7-R cells displayed a significant reduction of CTGF levels compared with Tamoxifen-responsive MCF7 cells (adjp<0.05; Fig. 9c). However, treatment with SER68 did not further reduce CTGF mRNA content. (Fig. 9).

Fig. 9
figure 9

Effect of SER79 and SER68 on Tamoxifen-resistant (MCF7-R) cells. a Estrogen starved MCF7-R were treated with SER79 (20 μM, 5 μM) or SER68 (20 μM) in presence of E2 (100 nM). b Estrogen-starved MCF7-R were treated with Tamoxifen (5 μM) in presence of E2 and SER79 (20 μM) or SER68 (20 μM). a,b As positive control, the cells were treated with E2 alone, in absence or in presence of SER (dotted line). After 72 h, cell viability was assessed by sulforhodamine B assay (see Methods). The results were reported as percentage of viable cells compared to positive control, considered as maximum viability (100%). c mRNA levels of CTGF were determined by qPCR (see Methods and Table 1) in MCF7-R cells upon treatment with SER68 (20 μM). Data were normalized on Ribosomal Protein S23 (Rps23) gene as internal standard and reported as CTGF mRNA levels in MCF7-R. a-c Graphs represent the mean ± SD of at least three independent triplicate experiments. * denotes statistically significant values compared with (b) positive control or (c) MCF7 cells (*adjp<0.05; **adjp<0.001). # denotes statistically significant values compared with untreated MCF7-R (#pval<0.05)

Full size image

Finally, we verified that the effect of SER79 and SER68 on MCF7, either responsive or resistant to Tamoxifen was not attributable to changes of expression of HT2C receptor. As shown in Supplementary Fig. 4, no difference in protein levels of HT2C receptors was detected upon SER treatment in all cell types (Fig. S4).

Discussion

New biological insights highlighted a role of serotonin in virtually all major organs outside the central nervous system [33]. Thus, 5-HT has numerous important peripheral functions in humans [18]. Among them, it is integral part of mammary epithelial homeostatic system in ensuring normal tissue function and becomes dysregulated in human breast tumor [34, 35]. 5-HT signaling has been related with cancer cell growth, differentiation, angiogenesis and metastasis, suggesting an association between its levels and tumor aggressiveness and/or prognosis [15, 18, 35]. Physiological responses to serotonin include both tumor-suppressing and tumor-promoting activities. Indeed, while controlling homeostatic regulatory mechanisms in normal mammary epithelium, 5-HT signaling appears to favor malignant progression of human BC [17]. Differences in the components of serotonin system, including the ability to synthesize 5-HT and/or specific receptors, may explain these opposite effects [15, 17]. Of note, transcriptomic and metabolomic data from breast tumor specimens highlighted the correspondence between poor prognosis and increased tumor-specific serotonin production [36]. Seven distinct families of 5-HT receptors are expressed in a tissue-specific manner across a variety of normal and tumor cells [37]. In BC, serotonin confers proliferative advantage to tumor cells by increasing proliferation rate and decreasing programmed cell death, mainly through 5-HT2A and 5-HT2C receptors [18, 26].

We previously synthesized serotoninergic receptor ligands with high affinity (in the nanomolar range) and selectivity binding profile towards 5-HT2A and 5-HT2C receptors [22]. Here, we analyzed the effect of such compounds on BC cell survival. Interestingly, we observed that their different ability to affect MCF7 (ER+, PR+, HER2−), SKBR3 (ER−, PR+, HER2+) and MDA-MB231 (ER−, PR−, HER2−) BC cell growth was not due to a lack of expression of 5-HT2 receptors but eventually attributable to their different molecular features, which also give them a different degree of aggressiveness. In addition, considering that structural analogies exist among serotoninergic receptors and that SER were selective, while not exclusive, for binding 5-HT2A and 5-HT2C, a possible involvement of other components of the serotoninergic receptor pattern, could not be excluded. It should also be noticed that several factors may influence the effect of SER on cell viability, including the ability to reach the receptor site and the intrinsic activity. Thus, the measure of receptor affinity not necessarily coincides to that of intrinsic activity of compounds. In line with this, even though the measure of receptor affinities were in nanomolar range, the effect of SER on cell viability has been observed at micromolar doses. This is also in agreement with a previous publication in a different cell type [37].

Interestingly, inhibition of cell viability in MCF7 cells is paralleled by cell cycle changes. For instance, upon treatment with different SER, MCF7 cells accumulate in G0/G1 phase and fail to proceed to S phase. Such effect does not occur in both SKBR3 and MDA-MB231. Hormone receptor-positive tumors obtain substantial benefit from treatment with Tamoxifen [20, 21]. We previously reported that Tamoxifen responsiveness of ER+ BC cells inversely correlates with Connective Tissue Growth Factor, providing additional clues to the hypothesis of its contribution to drug sensitivity in BC [31]. It has been described that inhibitors of serotoninergic pathway components reduced sphere-forming activity of breast tumor cell lines in dose-dependent fashion and synergized with docetaxel to shrink breast tumor xenografts [36]. In line with this concept, we provide evidence that some serotoninergic receptor ligands, namely SER79 and SER68, improve the effectiveness of Tamoxifen treatment on ER+ MCF7 BC cells modulating CTGF expression. CTGF may be triggered by serotonin and their association has been already described [38, 39].

Thus, our results identified new compounds able to target serotonin signaling, and in turn CTGF, and therefore potentially usable in combination with Tamoxifen improving its effectiveness on ER+ BC patients. However, CTGF levels are reduced in a cellular model of Tamoxifen resistance. In this same model, SER68 may restore Tamoxifen responsiveness, without further reducing CTGF levels. It should also be pointed out that SER68 and/or other SER exert an inhibitory action also on SKBR3 and MDA-MB231, although at a lower extent. Again, no modulation of CTGF levels have been detected in these cells, suggesting a potential involvement of ER and/or PR in SER-mediated effects on CTGF.

Adjuvant endocrine therapies may contribute to depression and anxiety in patients with cancer [40, 41]. Antidepressant medications, including antagonists of serotonin receptor and/or SSRIs, may be co-prescribed with Tamoxifen in BC [42]. However, some antidepressant agents interfere with Tamoxifen metabolism, compromising its efficacy [43]. In this regard, the use of SSRIs has been associated with increased tumor proliferative index in patients with late-stage BC compared to patients non-users of SSRIs [35]. Nevertheless, drug interactions involving Tamoxifen and antidepressant medications remain controversial [15, 23, 42]. The discovery of novel compounds directly targeting serotonin signaling may contribute to tailor new therapeutic strategies usable in combination with endocrine therapies, improving their efficacy for treating cancer patients.

Conclusions

We identified serotoninergic receptor ligands able to target serotonin signaling, and in turn CTGF, also ameliorating the sensitivity to Tamoxifen in ER+ BC cells. Thus, they represent new compounds potentially usable in combination with Tamoxifen improving its effectiveness on ER+ BC patients.

Availability of data and materials

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

5-HT:

5-Hydroxytryptamine, Serotonin

ER+ :

Estrogen Receptor Positive

SER:

Serotoninergic receptor ligands

BC:

Breast Cancer

CTGF:

Connective Tissue Growth Factor

SERMs:

Selective Estrogen Receptor Modulators

SSRIs:

Selective Serotonin Reuptake Inhibitors

E2:

Estradiol

References

  1. Baumgarten HG, Gother M. Serotoninergic Neurons and 5-HT Receptors in the CNS, 2000. vol. 129. Berlin: Springer-Verlag Berlin and Heidelberg GmbH & Co. KG; 1997.

    Google Scholar 

  2. Martin GR, Eglen RM, Hoyer D, Hamblin MW, Yocca F. Advances in serotonin receptor research; molecular biology, signal transmission, and therapeutics. New York: Ann NY Acad Sci; 1998.

    Google Scholar 

  3. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38:1083–152.

    Article  CAS  PubMed  Google Scholar 

  4. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav. 2002;71:533–54.

    Article  CAS  PubMed  Google Scholar 

  5. De Vry J. 5-HT1A receptor agonists: recent developments and controversialissues. Psychopharmacology. 1995;121:1–26.

    Article  PubMed  Google Scholar 

  6. File SE. Recent developments in anxiety, stress, and depression. Pharmacol Biochem Behav. 1996;54:3–12.

    Article  CAS  PubMed  Google Scholar 

  7. Neckelmann D, Bjorkum AA, Bjorvatn B, Ursin R. Sleep and EEG power spectral effects of the 5-HT1A agonist/antagonist NAN 190 alone and in combination with citalopram. Behav Brain Res. 1996;75:159–68.

    Article  CAS  PubMed  Google Scholar 

  8. Peroutka SJ. Serotonin Receptor Subtypes. CNS Drugs. 1995;4:18–28.

    Article  CAS  Google Scholar 

  9. Saxena PR. Serotonin receptors: subtypes, functional responses and therapeutic relevance. Pharmacol Ther. 1995;66:339–68.

    Article  CAS  PubMed  Google Scholar 

  10. Garnovskaya MN, van Biesen T, Hawes B, Ramos SC, Lefkowitz RJ, Raymond JR. Ras-Dependent Activation of fibroblast mitogen-activated protein kinase by 5- HT1A receptor via a G protein βγ-subunit-initiated pathway. Biochemistry. 1996;35:13716–22.

    Article  CAS  PubMed  Google Scholar 

  11. Cowen DS, Sowers RS, Manning DR. Activation of a mitogen-activated protein kinase (ERK2) by the 5-hydroxytryptamine 1A receptor is sensitive not only to inhibitors of phosphatidylinositol 3-kinase, but to an inhibitor of phosphatidylcholine hydrolysis. J Biol Chem. 1996;271:22297–300.

    Article  CAS  PubMed  Google Scholar 

  12. Adayev T, El-Sherif Y, Barua M, Banerjee P. Agonist stimulation of the serotonin1A receptor causes supression of anoxia-induced apoptosis via mitogen-activated protein kinase in neuronal HN2-5 cells. J Neurochem. 1999;72:1489–96.

    Article  CAS  PubMed  Google Scholar 

  13. Luo X, Persico AM, Lauder JM. Serotonergic regulation of somatosensory cortical development: Lessons from genetic mouse models. Dev Neurosci. 2003;25:173–83.

    Article  CAS  PubMed  Google Scholar 

  14. Corvino A, Fiorino F, Severino B, Saccone I, Frecentese F, Perissutti E, et al. The Role of 5-HT1A Receptor in the Cancer as a New Opportunity in Medicinal Chemistry. Curr Med Chem. 2018;25:3214–27.

    Article  CAS  PubMed  Google Scholar 

  15. Sarrouilhe D, Clarhaut J, Defamie N, Mesnil M. Serotonin and cancer: what is the link? Curr Mol Med. 2015;15:62–77.

    Article  CAS  PubMed  Google Scholar 

  16. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al. International union of pharmacology classification of receptors for 5-hydroxytryptamine. Pharmacol Rev. 1994;46:157–203.

    CAS  PubMed  Google Scholar 

  17. Pai VP, Marshall AM, Hernandez LL, Buckley AR, Horseman ND. Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival. Breast Cancer Res. 2009;11:R81.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Sola-Penna M, Paixão LP, Branco JR, Ochioni AC, Albanese JM, Mundim DM, et al. Serotonin activates glycolysis and mitochondria biogenesis in human breast cancer cells through activation of the Jak1/STAT3/ERK1/2 and adenylate cyclase/PKA, respectively. Br J Cancer. 2020;122:194–208.

    Article  CAS  PubMed  Google Scholar 

  19. D'Esposito V, Ambrosio MR, Giuliano M, Cabaro S, Miele C, Beguinot F, et al. Mammary Adipose Tissue Control of Breast Cancer Progression: Impact of Obesity and Diabetes. Front Oncol. 2020;10:1554.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.

    Article  Google Scholar 

  21. Patel HK, Bihani T. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacol Ther. 2018;186:1–24.

    Article  CAS  PubMed  Google Scholar 

  22. Fiorino F, Magli E, Kędzierska E, Ciano A, Corvino A, Severino B, et al. New 5-HT1A, 5HT2A and 5HT2C receptor ligands containing a picolinic nucleus: Synthesis, in vitro and in vivo pharmacological evaluation. Bioorg Med Chem. 2017;25:5820–37.

    Article  CAS  PubMed  Google Scholar 

  23. Fiorino F, Ciano A, Magli E, Severino B, Corvino A, Perissutti E, et al. Synthesis, in vitro and in vivo pharmacological evaluation of serotoninergic ligands containing an isonicotinic nucleus. Eur J Med Chem. 2016;110:133–50.

    Article  CAS  PubMed  Google Scholar 

  24. Fiorino F, Severino B, Magli E, Perissutti E, Frecentese F, Esposito A, et al. New Potent 5-HT2A Receptor Ligands Containing a N'-Cyanopicolinamidine Nucleus: Synthesis and In Vitro Pharmacological Evaluation. Eur J Med Chem. 2012;47:520–9.

    Article  CAS  PubMed  Google Scholar 

  25. Fiorino F, Severino B, De Angelis F, Perissutti E, Magli E, Frecentese F, et al. Synthesis and in vitro pharmacological evaluation of a new series of 5-HT1A 5-HT2A and 5-HT2C receptor ligands containing a norbornene nucleus. Pharmazie. 2009;64:555–64.

    CAS  PubMed  Google Scholar 

  26. Sonier B, Arseneault M, Lavigne C, Ouellette RJ, Vaillancourt C. The 5-HT2A serotoninergic receptor is expressed in the MCF-7 human breast cancer cell line and reveals a mitogenic effect of serotonin. Biochem Biophys Res Commun. 2006;343:1053–9.

    Article  CAS  PubMed  Google Scholar 

  27. Cheng YC, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099–108.

    Article  CAS  PubMed  Google Scholar 

  28. Scatchard G. The attraction of proteins for small molecules and ions. Ann N Y Acad Sci. 1949;51:660–72.

    Article  CAS  Google Scholar 

  29. Schlegel JR, Peroutka SJ. Nucleotide interactions with 5-HT1A binding sites directly labeled by [3H]-8-hydroxy-2-(di-n-propylamino)tetralin ([3H]-8-OH-DPAT). Biochem Pharmacol. 1986;35:1943–9.

    Article  CAS  PubMed  Google Scholar 

  30. Herndon JL, Ismaiel A, Ingher SP, Teitler M, Glennon RA. Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding. J Med Chem. 1992;35:4903–10.

    Article  CAS  PubMed  Google Scholar 

  31. Ambrosio MR, D'Esposito V, Costa V, Liguoro D, Collina F, Cantile M, et al. Glucose impairs tamoxifen responsiveness modulating connective tissue growth factor in breast cancer cells. Oncotarget. 2017;8:109000–17.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Guney Eskiler G, Cecener G, Tunca B, Egeli U. An in vitro model for the development of acquired tamoxifen resistance. Cell Biol Toxicol. 2016;32:563–81.

    Article  CAS  PubMed  Google Scholar 

  33. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60:355–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Stull MA, Pai V, Vomachka AJ, Marshall AM, Jacob GA, Horseman ND. Mammary gland homeostasis employs serotonergic regulation of epithelial tight junctions. Proc Natl Acad Sci U S A. 2007;104:16708–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Ballou Y, Rivas A, Belmont A, Patel L, Amaya CN, Lipson S, et al. 5-HT serotonin receptors modulate mitogenic signaling and impact tumor cell viability. Mol Clin Oncol. 2018;9:243–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Gwynne WD, Hallett RM, Girgis-Gabardo A, Bojovic B, Dvorkin-Gheva A, Aarts C, et al. Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts. Oncotarget. 2017;8:32101–16.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Fiorino F, Magli E, Perissutti E, Severino B, Frecentese F, Esposito A, et al. Synthesis of 1-naphtylpiperazine derivatives as serotoninergic ligands and their evaluation as antiproliferative agents. Eur J Med Chem. 2011;46:2206–16.

    Article  CAS  PubMed  Google Scholar 

  38. Kanakis GA, Grimelius L, Papaioannou D, Kaltsas G, Tsolakis AV. Can insulin-like growth factor 1 (IGF-1), IGF-1 receptor connective tissue growth factor and Ki-67 labelling index have a prognostic role in pulmonary carcinoids? Oncotarget. 2018;9:22653–64.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Jacobson A, Cunningham JL. Connective tissue growth factor in tumor pathogenesis. Fibrogenesis Tissue Repair. 2012;5:S8.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Kus T, Aktas G, Ekici H, Elboga G. Comparison of distress in breast cancer survivors treated with different adjuvant endocrine therapies: a single-centre cross-sectional study. Psych Clin Psychopharmacol. 2017;27:271–7.

    Google Scholar 

  41. Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry. 2008;165:1251–5.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Juurlink D. Revisiting the drug interaction between tamoxifen and SSRI antidepressants. BMJ. 2016;354:i5309.

    Article  PubMed  Google Scholar 

  43. Irarrázaval OME, Gaete GL. Antidepressants agents in breast cancer patients using tamoxifen: review of basic and clinical evidence. Rev Med Chil. 2016;144:1326–35.

    Google Scholar 

Download references

Acknowledgments

We express our gratitude to Dr. Domenico Liguoro for the technical support.

Funding

This research was funded by Regione Campania POR FESR 2014–2020–Objective 1.2.—Realization of Technology Platform to fight oncologic diseases (RARE PLAT NET, SATIN, and COEPICA Projects) and the Italian Association for the Cancer Research—AIRC (Grant IG19001).

Author information

Author notes

  1. Maria Rosaria Ambrosio and Elisa Magli contributed equally to this work.

Authors and Affiliations

  1. Institute for Experimental Endocrinology and Oncology “G. Salvatore” – National Research Council (IEOS-CNR), Via Pansini 5, 80131, Naples, Italy

    Maria Rosaria Ambrosio, Vittoria D’Esposito & Pietro Formisano

  2. Department of Translational Medicine, University of Naples “Federico II” (DiSMeT-UniNa), Via Pansini 5, 80131, Naples, Italy

    Maria Rosaria Ambrosio, Vittoria D’Esposito, Teresa Migliaccio, Giusy Mosca & Pietro Formisano

  3. Department of Pharmacy, University of Naples “Federico II” (UniNa), Via Montesano 49 -, 80131, Naples, Italy

    Elisa Magli, Giuseppe Caliendo, Rosa Sparaco & Ferdinando Fiorino

  4. Department of Medicine, Surgery and Neuroscience, University of Siena, Strada delle Scotte 6 –, 53100, Siena, Italy

    Paola Massarelli

Authors
  1. Maria Rosaria Ambrosio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elisa Magli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppe Caliendo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rosa Sparaco
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paola Massarelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vittoria D’Esposito
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Teresa Migliaccio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Giusy Mosca
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ferdinando Fiorino
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Pietro Formisano
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

M.R.A., E.M., F.F. and P.F. conceived the study and designed the work; M.R.A., G.C., R.S., T.M. and G.M. performed the experiments; M.R.A., E.M., P.M. and V.D. acquired and analyzed the data; M.R.A., E.M., F.F. and P.F. drafted the manuscript. All authors contributed to data interpretation and discussion, also edited and approved the final manuscript. All authors have read and agreed to the published version of the manuscript.

Corresponding author

Correspondence to Pietro Formisano.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Figure S1.

Effect of vehicle on cell viability of (a) MCF7, (b) SKBR3 and (c) MDA-MB231.

Additional file 2: Figure S2.

Effect of SER on SKBR3 and MDA-MB231 cells.

Additional file 3: Figure S3.

Establishment of MCF7 Tamoxifen resistant (MCF7-R) cells.

Additional file 4: Figure S4.

5-HT2C protein in MCF7, Tamoxifen-cultured MCF7 and MCF-R cells in absence or in presence of SER.

Additional file 5.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ambrosio, M.R., Magli, E., Caliendo, G. et al. Serotoninergic receptor ligands improve Tamoxifen effectiveness on breast cancer cells. BMC Cancer 22, 171 (2022). https://doi.org/10.1186/s12885-021-09147-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12885-021-09147-y

Keywords

BMC Cancer

ISSN: 1471-2407

Contact us